Brave Asset Management’s Achilles Therapeutics ACHL Stock Holding History

Brave Asset Management’s Portfolio ACHL Stock Details ACHL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-10,000	Closed	-$14.5K	–	184
2025 Q1	$14.5K	Hold	10,000	–	–	﹤0.01%	159
2024 Q4	$11.4K	Hold	10,000	–	–	﹤0.01%	163
2024 Q3	$10.2K	Hold	10,000	–	–	﹤0.01%	166
2024 Q2	$8.15K	Hold	10,000	–	–	﹤0.01%	159
2024 Q1	$12.5K	Buy	+10,000	New	+$10.8K	﹤0.01%	165

Other funds holding ACHL

RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

Brave Asset Management's ACHL Position: Q2 2025 in Review

Brave Asset Management sold out of Achilles Therapeutics (ACHL) in Q2 2025, closing a stake of 10,000 shares — an estimated $14.5K sold.

Brave Asset Management first reported a position in ACHL in Q1 2024 and held it in 5 quarters. The position peaked at $14.5K in Q1 2025. 2 funds tracked by Wall St. Rank hold ACHL as of Q2 2025.

Brave Asset Management reported no remaining Achilles Therapeutics position as of Q2 2025 after selling out during the quarter.
Brave Asset Management sold 10,000 Achilles Therapeutics shares in Q2 2025, an estimated $14.5K.
Brave Asset Management first reported a position in Achilles Therapeutics in Q1 2024 and held it in 5 quarters.
Brave Asset Management's Achilles Therapeutics position peaked at $14.5K in Q1 2025.
2 funds tracked by Wall St. Rank held Achilles Therapeutics as of Q2 2025.

Based on Brave Asset Management's 13F filing for Q2 2025, filed 16 Jul 2025.